Welcome!

News Feed Item

Lorus Therapeutics Reports Second Quarter Results for Fiscal 2014

TORONTO, ONTARIO -- (Marketwired) -- 01/07/14 -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company") reported financial results for the three and six months ended November 30, 2013 and provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.

The net loss for the quarter ending November 30, 2013 was $2.8 million, or ($0.06) per share, compared with a net loss of $1.6 million, or ($0.04) per share for the same period in the prior year. Total cash, cash equivalents and investments as of November 30, 2013 totaled $1.7 million.

"The recent quarter was marked by significant corporate and product development events that well position Lorus for the advancement of our lead program LOR-253 for the treatment of acute myeloid leukemia (AML) and potentially other hematologic cancers," said William G. Rice, Ph.D., Chairman and Chief Executive Officer. "Notably, with a new management team in place, we have redirected our development efforts and completed a capital raise that will provide adequate runway for the Company for the foreseeable future."

SECOND QUARTER 2014 AND RECENT HIGHLIGHTS

Corporate Highlights


--  On October 28, 2013, the Company appointed William G. Rice, Ph.D., as
    Chief Executive Officer and Chairman of the Board. Aiping H. Young,
    M.D., Ph.D. continues as President and Chief Operating Officer. Lorus
    also appointed Daniel D. Von Hoff, M.D., to serve as a special advisor,
    fulfilling the role of Senior Vice President of Medical Affairs.
--  On October 29, 2013, Brian Druker, M.D., was appointed as the Chair of
    Lorus' Scientific Advisory Board.
--  On December 2, 2013, Avanish Vellanki was appointed Chief Business
    Officer overseeing global business development, licensing and corporate
    strategy, and Gregory K. Chow was appointed Chief Financial Officer with
    responsibility for corporate finance and accounting functions.
--  Subsequent to the quarter end on December 10, 2013, Lorus completed a
    public offering of common shares. Lorus issued a total of 12,730,000
    common shares at a price of $0.55 per common share for aggregate gross
    proceeds of $7,001,500.
--  During the month of November 2013, 4.445 million warrants were exercised
    for proceeds of $1.93 million.

LOR-253 Highlights


--  On October 29, 2013, Lorus announced that the Company will pursue the
    clinical development of its lead program, LOR-253, in acute myeloid
    leukemia (AML) and certain hematologic malignancies based on recent
    research and insights into AML. The Company plans to continue its
    investigation of the clinical utility of LOR-253 in the treatment of a
    patient population with suppressed KLF4 in AML, Myelodysplastic
    Syndromes and potentially other hematologic malignancies. The Company is
    planning to initiate a Phase 1/2 in 2014.
--  In September 2013, Lorus presented a poster entitled "OPEN-LABEL, PHASE
    1 STUDY OF LOR-253 HCl IN PATIENTS WITH ADVANCED OR METASTATIC SOLID
    TUMORS" at the European Cancer Congress 2013. At the targeted dose, LOR-
    253 demonstrated an absence of significant toxicities, evidence of a
    rapid distribution phase and prolonged terminal phase of greater than
    144 hours and antitumor activity with sustained stable disease (SD)
    determined by RECIST that was confirmed over 4 to 8 cycles. Further, SD
    was observed in 80% (4/5) of evaluable patients, and maintained on
    termination with dose-limiting toxicities seen only at the maximum
    administered dose, confirming the safety margin of the drug.

FINANCIAL RESULTS

Net loss for the three months ended November 30, 2013 was $2.8 million ($0.06 per share) compared to $1.6 million ($0.04 per share) in the same period in the prior year. The Company incurred a net loss of $3.9 million ($0.09 per share) for the six months ended November 30, 2013 compared to $2.9 million ($0.07 per share) during the same period in the prior year.

In the three-month period ended November 30, 2013, research and development expenditures decreased by $119,000. The decrease between the comparable three month periods was due to reduced spending on the LOR-253 and IL-17E programs until additional financing was secured, which was partially offset by increased stock based compensation and deferred share unit costs. General and administrative expenses increased $1.2 million in the three months ended November 30, 2013, compared with the prior year period, due to increased stock-based compensation, deferred share unit and salary costs associated with the appointment of new executives and an increase in Lorus' share price during the quarter.

In the six month period ended November 30, 2013, research and development expenditures decreased by $161,000 due to reduced program activity as the Phase I clinical trial completed and future development was placed on hold, partially offset by higher stock based compensation and deferred share unit costs. General and administrative expenses increased by $1.1 million in the six months ended November 30, 2013 compared with the prior year period due primarily to increased stock based compensation, deferred share unit and salary costs associated with the appointment of new executives and an increase in share price during the three month period ended November 30, 2013.

At November 30, 2013, Lorus had cash and cash equivalents of $1.7 million compared to $653,000 at May 31, 2013. Subsequent to the quarter end on November 30, 2013, the Company raised gross proceeds of approximately $7 million through a public offering of its common shares.

For further details and to view the Company's May 31, 2013 Audited Consolidated Financial Statements and Management's Discussion and Analysis, please see the Company's filings on www.sedar.com and on www.lorusthera.com.


Lorus Therapeutics Inc.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(unaudited)
                                        Three     Three       Six       Six
                                       months    months    months    months
(amounts in 000's of Canadian           ended     ended     ended     ended
 Dollars except for per common share Nov. 30,  Nov. 30,  Nov. 30,  Nov. 30,
 data)                                   2013      2012      2013      2012
----------------------------------------------------------------------------
REVENUE                              $      -  $      -  $      -  $      -
----------------------------------------------------------------------------

EXPENSES
Research and development                  791       910     1,406     1,567
General and administrative              1,938       714     2,389     1,321
----------------------------------------------------------------------------
Operating expenses                      2,729     1,624     3,795     2,888
Finance expense                            70         -       106         6
Finance income                             (1)      (11)       (2)      (17)
----------------------------------------------------------------------------
Net financing expense (income)             69       (11)      104       (11)
----------------------------------------------------------------------------
Net loss and total comprehensive
 loss for the period                    2,798     1,613     3,899     2,877
----------------------------------------------------------------------------
Basic and diluted loss per common
 share                               $   0.06  $   0.04  $   0.09  $   0.07
----------------------------------------------------------------------------

Weighted average number of common
 shares outstanding used in the
 calculation of basic and diluted
 loss per common share (000's)         43,733    42,251    42,992    42,251
----------------------------------------------------------------------------

About Lorus

Lorus is a biopharmaceutical company targeting essential apoptosis pathways to deliver transformational cancer drugs. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used alone and in combination with other drugs to successfully treat specific forms of cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR. Additional information on Lorus Therapeutics is available at www.lorusthera.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our ability to obtain financing or partnerships, the establishment of corporate alliances, our ability to maintain current and future corporate alliances, our ability to fund or reach developmental milestones, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Contacts:
Lorus Therapeutics Inc.
Greg Chow
CFO
416-798-1200
[email protected]
www.lorusthera.com

BCC Partners
Karen L. Bergman
650-575-1509
[email protected]

BCC Partners
Susan Pietropaolo
845-638-6290
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Adobe is changing the world though digital experiences. Adobe helps customers develop and deliver high-impact experiences that differentiate brands, build loyalty, and drive revenue across every screen, including smartphones, computers, tablets and TVs. Adobe content solutions are used daily by millions of companies worldwide-from publishers and broadcasters, to enterprises, marketing agencies and household-name brands. Building on its established design leadership, Adobe enables customers not o...
SYS-CON Events announced today the Enterprise IoT Bootcamp, being held November 1-2, 2016, in conjunction with 19th Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA. Combined with real-world scenarios and use cases, the Enterprise IoT Bootcamp is not just based on presentations but with hands-on demos and detailed walkthroughs. We will introduce you to a variety of real world use cases prototyped using Arduino, Raspberry Pi, BeagleBone, Spark, and Intel Edison. Y...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
SYS-CON Events announced today that Sheng Liang to Keynote at SYS-CON's 19th Cloud Expo, which will take place on November 1-3, 2016 at the Santa Clara Convention Center in Santa Clara, California.
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT de...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to connect your brand strategy with the right consumer. 24Notion ranked #12 on Corporate Social Responsibility - Book of List.